2026-04-18T07:53:50Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4692662025-07-29T21:52:46Zcom_2072_98col_2072_378192

The Conners Continuous Performance Test CPT3 ™ : Is it a reliable marker to predict neurocognitive dysfunction in Myalgic encephalomyelitis/chronic fatigue syndrome? Fernández-Quirós, Judith Lacasa-Cazcarra, Marcos Alegre Martín, José Sanmartin Sentañes, Ramon Almirall, Míriam Launois-Obregón, Patricia Castro-Marrero, Jesús Rodríguez-Urrutia, Amanda Navarro-Sanchis, Jose A. Ramos-Quiroga, Josep Antoni Universitat Autònoma de Barcelona Neuropsychological test Cognitive impairments Continuous performance test CPT3 ™ Neurocognitive dysfunction Central Sensitization Syndromes Chronic fatigue syndrome The main objective is to delimit the cognitive dysfunction associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in adult patients by applying the Continuous Performance Test (CPT3 ™). Additionally, provide empirical evidence on the usefulness of this computerized neuropsychological test to assess ME/CFS. The final sample (n = 225; 158 Patients/67 Healthy controls) were recruited in a Central Sensitization Syndromes (CSS) specialized unit in a tertiary hospital. All participants were administered this neuropsychological test. There were significant differences between ME/CFS and healthy controls in all the main measures of CPT3 ™. Mainly, patients had a worse indicator of inattentiveness, sustained attention, vigilance, impulsivity, slow reaction time, and more atypical T-scores, which is associated with a likelihood of having a disorder characterized by attention deficits, such as Attention Deficit Hyperactivity Disorder (ADHD). In addition, relevant correlations were obtained between the CPT3 ™ variables in the patient's group. The most discriminative indicators of ME/CFS patients were Variability and Hit Reaction Time, both measures of response speed. The CPT3 ™ is a helpful tool to discriminate neurocognitive impairments from attention and response speed in ME/CFS patients, and it could be used as a marker of ME/CFS severity for diagnosing or monitoring this disease. 2023 Article https://ddd.uab.cat/record/280993 urn:10.3389/fpsyg.2023.1127193 urn:oai:ddd.uab.cat:280993 urn:pmcid:PMC10008938 urn:pmc-uid:10008938 urn:pmid:36923151 urn:oai:pubmedcentral.nih.gov:10008938 urn:oai:egreta.uab.cat:publications/d15c608d-f2fa-4eca-88bf-279cb6063057 eng Frontiers in psychology ; Vol. 14 (february 2023) open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf